Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
TNFRSF1B	7133	LITHIUM	CHEMBL2146126		NCI	15565432
TNFRSF1B	7133	ETANERCEPT	CHEMBL1201572		DrugBank	11752352
TNFRSF1B	7133	DACTINOMYCIN	CHEMBL1554		NCI	11125300
TNFRSF1B	7133	CARBAMAZEPINE	CHEMBL108		NCI	15565432
TNFRSF1B	7133	DIDANOSINE	CHEMBL1460		NCI	9430255
TNFRSF1B	7133	STAVUDINE	CHEMBL991		NCI	9430255

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
TNFRSF1B	rs1061622	G	infliximab	efficacy	yes	Only the abstract of this article is available.	Allele G is associated with decreased response to infliximab in people with Arthritis, Rheumatoid as compared to allele T.	18565259	981352439
TNFRSF1B	rs1061622	TT	rituximab	efficacy	no	No significant association was seen between genotype and whether a patient was a "responder" or a "non-responder". "Responders" had a post-rituximab disease activity score (DAS28) of lower than 5.1 and a DAS28 variation between baseline and post-treatment higher than 0.6. Please note alleles have been complemented to the plus chromosomal strand.	Genotype TT is not associated with response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes GG + GT.	22129793	982047110
TNFRSF1B	rs1061631	AA	Tumor necrosis factor alpha	efficacy	yes	Treatments included Methotrexate, Leflunomide, Sulfasalazine, Infliximab, Etanercept, Adalimumab, Abatacept, Rituximab, Tocilimumab, and others.	Genotype AA is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.	25850964	1444704305
TNFRSF1B	rs1061622	GG	Tumor necrosis factor alpha	efficacy	yes	Treatments included Methotrexate, Leflunomide, Sulfasalazine, Infliximab, Etanercept, Adalimumab, Abatacept, Rituximab, Tocilimumab, and others.	Genotype GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes GT + TT.	25850964	1444704286
TNFRSF1B	rs1061622	GG + GT	adalimumab	efficacy	yes	Patients treated for the first time with one of these 4 biological therapies and completed at least 6 months of treatment. All the patients had moderate-severe psoriasis despite previous conventional treatment, or had contraindication with phototherapy, acitretin, methotrexate, and cyclosporine.	Genotypes GG + GT are associated with decreased response to adalimumab, etanercept, infliximab or ustekinumab in people with Psoriasis as compared to genotype TT.	25537528	1447959074
TNFRSF1B	rs1061624	AG + GG	adalimumab	efficacy	yes	as measured by PASI75 at 6 months.	Genotypes AG + GG is associated with decreased response to adalimumab or infliximab in people with Psoriasis as compared to genotype AA.	29192552	1449155535
TNFRSF1B	rs1061622	GT	etanercept	efficacy	yes	Response to etanercept was determined using the Assessment in Ankylosing Spondylitis 20 (ASAS20) and Assessment in Ankylosing Spondylitis 40 (ASAS40). Patients with the GT genotype had a significantly decreased response to etanercept at 12 months after the initiation of etanercept treatment compared to patients with the GG or TT genotypes. However, there was no significant difference in response between the different genotypes at 3 months after initiation of treatment.	Genotype GT is associated with decreased response to etanercept in people with Spondylitis, Ankylosing as compared to genotypes GG + TT.	30075559	1449713732
TNFRSF1B	rs1061624	GG	Tumor necrosis factor alpha	efficacy	no	Treatments included Methotrexate, Leflunomide, Sulfasalazine, Infliximab, Etanercept, Adalimumab, Abatacept, Rituximab, Tocilimumab, and others.	Genotype GG is not associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.	25850964	1444704313
TNFRSF1B	rs3397	CC	Tumor necrosis factor alpha	efficacy	yes	Treatments included Methotrexate, Leflunomide, Sulfasalazine, Infliximab, Etanercept, Adalimumab, Abatacept, Rituximab, Tocilimumab, and others.	Genotype CC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.	25850964	1444704297
TNFRSF1B	rs3397	C	Tumor necrosis factor alpha	efficacy	yes	Treatments included Methotrexate, Leflunomide, Sulfasalazine, Infliximab, Etanercept, Adalimumab, Abatacept, Rituximab, Tocilimumab, and others.	Allele C is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.	25850964	1444704274